OptimAIze Consulting AI
2025-05-20 05:52:53

AI Startup OptimAIze Consulting Partners with Osaka University for Dementia AI Research

Collaboration between Innovators in AI and Dementia Care



In a significant move towards enhancing dementia diagnosis and care, the AI startup OptimAIze Consulting, based in Tokyo, has officially entered into a joint research agreement with the Graduate School of Medicine at Osaka University. This collaboration, also involving i-Brain Science, a company specializing in dementia diagnosis solutions, aims to develop advanced AI algorithms for screening Mild Cognitive Impairment (MCI) and early-stage dementia patients.

The Partnership Details


OptimAIze Consulting, led by CEO Takashi Sekido, along with Ryuichi Morishita and Akiko Takeda from Osaka University's Clinical Genetic Therapy Chair, will work together under the framework established on May 19, 2025. This partnership is designed to integrate their expertise in AI with the clinical knowledge of dementia care, fostering a collaborative environment that could greatly influence early detection methods.

The heart of this project lies in the development of a second-generation app, aimed specifically at improving the accuracy of screening for MCI and early dementia. The collaborating companies plan to focus on refining the functionality of 'Mirevo®,' a Software as a Medical Device (SaMD) that uses gaze tracking technology to assess cognitive functions quantitatively. This innovative technology has already demonstrated a strong correlation with traditional assessments such as the Mini Mental State Examination (MMSE).

The Need for Early Detection


As dementia cases continue to rise in Japan, with approximately six million affected individuals and over 10 million when including MCI, the urgency for early detection and intervention has never been more pressing. The approval of anti-amyloid beta antibody treatments emphasizes the need for accurate patient selection, making this research pivotal for improving healthcare outcomes.

Despite the advancements, current testing methods present significant challenges—previously reliable MMSE results can still mask early stages of dementia or MCI, leading to missed diagnoses. Furthermore, detailed evaluations like ADAS or WMS can be time-consuming and impractical for general practitioners to administer routinely.

Addressing Clinical Challenges


This collaborative research aims to tackle these challenges by creating an AI algorithm capable of identifying MCI and early dementia within just three minutes of testing. By streamlining the diagnostic process, the project aspires to enable healthcare professionals to deliver timely and effective care to patients who may otherwise remain undiagnosed.

The implication of this innovation is far-reaching. It not only seeks to reduce the number of patients who slip through the cracks in the screening process but also aims to establish a more efficient referral pathway from general practitioners to specialized medical facilities. This could enhance the overall management of dementia cases, particularly for patients eligible for emerging treatments.

The Anticipated Impact


Some of the expected outcomes from this collaboration include:
  • - Improved Efficiency in Referrals: Facilitating a smoother transfer of patients from general care to specialist centers.
  • - Prevention of Missed Diagnoses: Ensuring that patients who qualify for anti-amyloid beta treatments are properly identified.
  • - Enhanced Screening Accuracy: Utilizing gaze data to assist in differential diagnosis of dementia.
  • - Augmented Awareness for MCI Detection: Supporting the early identification of conditions that could lead to more severe dementia.

About OptimAIze Consulting


Emerging from a team of AI specialists at the University of Tokyo, OptimAIze Consulting is dedicated to delivering cutting-edge AI consulting and algorithm development. Their range of services encompasses various AI technologies, including deep learning, image analysis, and explainable AI (XAI). The company aims to provide tailored solutions to enhance operational efficiency for clients in healthcare, pharmaceuticals, and research institutions.

To further support this, they are offering a limited-time free consultation for organizations interested in implementing AI technologies within their operations.

For more information or to reach out for consultations, visit: OptimAIze Consulting Contact Page

Company Overviews


  • - i-Brain Science Inc.
- Location: 2-8 Yamada Hill, Suita City, Osaka Prefecture
- CEO: Kentaro Takamura
- Established: November 2019
- Services: Development and sales of medical device programs
- Website: i-Brain Science

  • - OptimAIze Consulting, Inc.
- Location: 4-3-11 Roppongi, Minato City, Tokyo
- CEO: Takashi Sekido
- Established: July 2024
- Services: AI consulting and system development
- Website: OptimAIze Consulting

  • - Osaka University
- Location: 1-1 Yamada Hill, Suita City, Osaka Prefecture
- President: Atsushi Kumano

This strategic partnership holds immense promise for the future of dementia diagnosis and care, embodying the integration of technology in healthcare to advance patient outcomes and enhance quality of life.


画像1

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.